Contineum Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Contineum Therapeutics, Inc. (CTNM) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 2.36 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-07-30
- Contineum Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 325.00K shares, a 31.98% decline year-over-year.
- Contineum Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 2.03M shares, a 87.92% increase year-over-year.
- Contineum Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Contineum Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 41.00K shares, a 8.89% decline year-over-year.
- Contineum Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 1.60M shares, a 4.74% increase from fiscal 2024.
- Contineum Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.53M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 325.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | 2.36M shares 10-Q · filed 2026-07-30 | 2.36M shares derived: sum of 3 quarters · filed 2026-07-30 | 2.40M shares derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | 2.03M shares 10-Q · filed 2026-05-05 | 2.03M shares derived: sum of 2 quarters · filed 2026-05-05 | 2.07M shares derived: sum of 3 quarters · filed 2026-05-05 | 2.55M shares derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 41.00K shares derived: sum of 2 quarters · filed 2026-03-05 | 518.80K shares derived: sum of 3 quarters · filed 2026-03-05 | 1.60M shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 41.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | 518.80K shares derived: sum of 2 quarters · filed 2025-10-30 | 1.60M shares 10-Q · filed 2025-10-30 | 1.62M shares derived: sum of 4 quarters · filed 2025-10-30 |
| 2025-06-30 | 477.80K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 1.56M shares 10-Q · filed 2025-08-05 | 1.58M shares derived: sum of 3 quarters · filed 2025-08-05 | 1.63M shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 1.08M shares 10-Q · filed 2025-05-14 | 1.11M shares derived: sum of 2 quarters · filed 2025-05-14 | 1.15M shares derived: sum of 3 quarters · filed 2025-05-14 | 2.37M shares derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-12-31 | 23.80K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 68.80K shares derived: sum of 2 quarters · filed 2025-03-06 | 1.29M shares derived: sum of 3 quarters · filed 2025-03-06 | 1.53M shares 10-K · filed 2025-03-06 |
| 2024-09-30 | 45.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 1.26M shares derived: sum of 2 quarters · filed 2024-11-06 | 1.50M shares 10-Q · filed 2024-11-06 | |
| 2024-06-30 | 1.22M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 1.46M shares 10-Q · filed 2024-08-14 | ||
| 2024-03-31 | 242.28K shares 10-Q · filed 2024-05-16 | |||
| 2023-06-30 | 0.00 shares 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |